ClinicalTrials.gg
RecruitingNCT06108492Updated Dec 3, 2024

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

A Phase 1 interventional study of SHR-2005 in Intermediate and High-risk Non-muscle Invasive Bladder Cancer, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
18th of 47
170 · median 114
Started
2023
with 9 others
Phase 1
5 of 50
5 open now
Primary completion
2026-12
later than 18 of 43 live
Registered
16th of 50
by date
Lead sponsor
2 of 50
Shanghai Hengrui Pharmaceutical Co., Ltd.

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 18th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2023, is one of 5 in phase 1, reaches primary completion later than 18 of the 43 other live ones, and was the 16th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle invasive bladder cancer.

03

Conditions studied

  • Intermediate and High-risk Non-muscle Invasive Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form;
  2. ≥18 years of age, either sex;
  3. Previous pathological was diagnosed as intermediate or high-risk NMIBC ;
  4. performance status of 0-1;
  5. ≥ 2 years;
  6. Adequate bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Received TURBT or other surgical treatment or radiotherapy for bladder lesions within 2 weeks before the first administration;
  2. Patients who were receiving treatment in other clinical trials or less than 4 weeks from the end of the first administration in this study;
  3. History of serious cardiovascular and cerebrovascular diseases;
  4. Severe infection within 2 weeks prior to the first dose;
  5. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per v5.0;
  6. Oversize surgery or severe trauma within 4 weeks before the first use of research drugs;
  7. Previously received any TNFR agonist antibody therapy, such as OX40, CD137, CD27, CD357 antibodies.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    SHR-2005

    Only one arm with SHR-2005

    Drug: SHR-2005

Interventions

  • DrugSHR-2005

    In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period. In indication Expansion: Indications will be selected to evaluate preliminary efficacy.

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    Time frame: From Day 1 to Day 21

  2. Maximum tolerated dose (MTD)

    Time frame: From Day 1 to Day 21

  3. Incidence and severity of adverse events (AEs) ([CTCAE] v5.0)

    Time frame: From Day 1 to 90 days after last dose

  4. RP2D(Recommended Phase 2 dose)

    Time frame: From Day 1 to 90 days after last dose

Secondary outcomes

  1. PK parameter: Tmax of SHR-2005

    Time to maximum concentration of SHR-2005

    Time frame: approximately 24 months

  2. PK parameter: Cmax of SHR-2005

    Maximum concentration of SHR-2005

    Time frame: approximately 24 months

  3. PK parameter: AUC0-∞ of SHR-2005

    area under the concentration-time curve from time 0 to infinity of SHR-2005

    Time frame: approximately 24 months

  4. Immunogenicity of SHR-2005

    Anti- SHR-2005 antibody (ADA)

    Time frame: approximately 24 months

  5. Duration of response (DoR)

    Evaluated using RECIST 1.1

    Time frame: approximately within 36 months

  6. Disease control rate (DCR)

    Evaluated using RECIST 1.1

    Time frame: approximately within 36 months

  7. Progression-free survival (PFS)

    Evaluated using RECIST 1.1

    Time frame: approximately within 36 months

  8. Amount_recovered and Percent_recovered

    The Amount _ recovered and Percent _ recovered of SHR-2005 in urine after intravesical instillation.

    Time frame: approximately 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 61. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Nov 28, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Sep 30, 2027
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06108492
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Nov 28, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Dec 3, 2024

Study contacts

Shouwei Zhao
Contact
shouwei.zhao@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion